HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delle Chiaie, R. Articles by Scapicchio, P. Search for Related Content PubMed PubMed Citation Articles by Delle Chiaie, R. Articles by Scapicchio, P. Agricola Articles by Delle Chiaie, R. Articles by Scapicchio, P.

Efficacy and tolerability of oral and intramuscular S-adenosyl- L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies^1,2,3,4

¹ From III Clinica Psichiatrica "La Sapienza" University, Rome (RDC and PP); Fondazione Italiana per lo Studio Della Schizofrenia, Rome (RDC and PP); and Società Italiana di Psichiatria, Rome (PS).

Background: S-Adenosyl-L-methionine (SAMe), a natural compound, is the most important methyl donor in the central nervous system. In several clinical trials, SAMe showed antidepressant activity.

Objective: Two multicenter studies were conducted in patients with a diagnosis of major depressive episode [baseline score on the 21-item Hamilton Depression Rating Scale (HAM-D) 18] to confirm the efficacy and safety of SAMe in the treatment of major depression. In the first study (MC3), 1600 mg SAMe/d was given orally; whereas, in the second study (MC4), 400 mg SAMe/d was given intramuscularly. In both studies, the effects of SAMe were compared with those of 150 mg imipramine/d given orally in a double-blind design.

Design: In MC3, 143 patients received oral SAMe and 138 patients received imipramine for 6 wk. In MC4, 147 patients received SAMe intramuscularly and 148 patients received imipramine for 4 wk. In both studies the 2 main efficacy measures were the final HAM-D score and the percentage of responders to Clinical Global Impression at the endpoint. Secondary efficacy measures were the endpoint Montgomery-Asberg Depression Rating Scale scores and the percentage of responders, responders being those patients showing a decrease in HAM-D score of 50% from baseline.

Results: In both studies, the results of SAMe and imipramine treatment did not differ significantly for any efficacy measure. However, significantly fewer adverse events were observed in the patients treated with SAMe.

Conclusions: The antidepressive efficacy of 1600 mg SAMe/d orally and 400 mg SAMe/d intramuscularly is comparable with that of 150 mg imipramine/d orally, but SAMe is significantly better tolerated.

Key Words: S-Adenosyl-L-methionine • SAMe • imipramine • major depression • efficacy • tolerability

This article has been cited by other articles:

				U. WERNEKE, T. TURNER, and S. PRIEBE Complementary medicines in psychiatry: Review of effectiveness and safety The British Journal of Psychiatry, February 1, 2006; 188(2): 109 - 121. [Abstract] [Full Text] [PDF]

				Antidepressant Effects of SAMe, Redux Journal Watch Psychiatry, December 19, 2002; 2002(1219): 7 - 7. [Full Text]

				C. S Lieber and L. Packer S-Adenosylmethionine: molecular, biological, and clinical aspects--an introduction Am. J. Clinical Nutrition, November 1, 2002; 76 (5): 1148S - 1150S. [Abstract] [Full Text] [PDF]

				B. Saletu, P. Anderer, C. Di Padova, A. Assandri, and G. M. Saletu-Zyhlarz Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography Am. J. Clinical Nutrition, November 1, 2002; 76 (5): 1162S - 1171S. [Abstract] [Full Text] [PDF]